Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the phase I and phase II metabolism of most clinically prescribed drugs. As polymorphisms in these genes may alter enzyme activities, most prescribed drugs will differ in their efficacy and side effects. In prior work, we showed that besides polymorphisms in CYP450, those in SULT and UGT also give rise to different serum levels of some drug metabolites than detected in wild-type carriers of the genes [1]. [...
Variation of a short (TA)(n) repeat sequence (rs8175347) covering the TATA box of UGT1A1 (UDP-glucur...
UGT1A4 is primarily expressed in the liver and exhibits catalytic activities for various drugs. Amon...
Includes bibliographical references (leaves 109-130).Although the incidence and mortality due to the...
Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the...
Background: Genetic variation in glucuronosyltransferases (UGT) is crucial in drug metabolism and ri...
This review is focused on the genetic variation of sulfotransferases (SULTs) and cytochromes (CYPs)...
The aim of this study is to describe the diversity of four cytochrome and four sulfotransferase pol...
Pharmacogenetics enables personalised therapy based on genetic profiling and is increasingly applied...
Glucuronidation, mediated by UDP-glucuronosyltransferase enzymes (UGTs), is a major phase II biotran...
Pharmacogenetics of drug metabolising enzymes has been well studied in Caucasians and Asians, but re...
Genetic diversity is greater in Africa than in other continental populations. Genetic variability in...
Genetic diversity is greater in Africa than in other continental populations. Genetic variability in...
Background: Drug metabolism genes are variable in populations. African populations are highly geneti...
Over the past decade, the number of pharmacogenetic tests has increased considerably, allowing for t...
Objectives: This study focuses on identifying variations in selected CYP genes related to treatment ...
Variation of a short (TA)(n) repeat sequence (rs8175347) covering the TATA box of UGT1A1 (UDP-glucur...
UGT1A4 is primarily expressed in the liver and exhibits catalytic activities for various drugs. Amon...
Includes bibliographical references (leaves 109-130).Although the incidence and mortality due to the...
Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the...
Background: Genetic variation in glucuronosyltransferases (UGT) is crucial in drug metabolism and ri...
This review is focused on the genetic variation of sulfotransferases (SULTs) and cytochromes (CYPs)...
The aim of this study is to describe the diversity of four cytochrome and four sulfotransferase pol...
Pharmacogenetics enables personalised therapy based on genetic profiling and is increasingly applied...
Glucuronidation, mediated by UDP-glucuronosyltransferase enzymes (UGTs), is a major phase II biotran...
Pharmacogenetics of drug metabolising enzymes has been well studied in Caucasians and Asians, but re...
Genetic diversity is greater in Africa than in other continental populations. Genetic variability in...
Genetic diversity is greater in Africa than in other continental populations. Genetic variability in...
Background: Drug metabolism genes are variable in populations. African populations are highly geneti...
Over the past decade, the number of pharmacogenetic tests has increased considerably, allowing for t...
Objectives: This study focuses on identifying variations in selected CYP genes related to treatment ...
Variation of a short (TA)(n) repeat sequence (rs8175347) covering the TATA box of UGT1A1 (UDP-glucur...
UGT1A4 is primarily expressed in the liver and exhibits catalytic activities for various drugs. Amon...
Includes bibliographical references (leaves 109-130).Although the incidence and mortality due to the...